A metabolic enzyme as a potential new target for cancer immune therapies

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system. This was discovered by scientists at the German Cancer Research Center (DKFZ) and the Berlin Institute of Health (BIH). The enzyme that activates the dioxin receptor is produced in large quantities by tumor cells. In the future, substances that inhibit IL4I1 could open up new opportunities for cancer therapy. The scientists have now published their results in the journal Cell.